Work

Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PACE Trial

Year: 2013
Type: article
Source: Blood
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: closed
OpenAlex ID: W34826755
FWCI: 1.706
Cites:
Cited by: 13
Related to: 10